
OSTX Stock Forecast & Price Target
OSTX Analyst Ratings
Bulls say
OS Therapies Inc. has demonstrated strong clinical efficacy for its treatment OST-HER2, achieving a two-year overall survival rate of 75% in patients with fully resected pulmonary metastatic osteosarcoma, significantly outperforming the historical control rate of 40%. The upcoming biomarker correlation dataset anticipated for November 2025 is poised to enhance the regulatory stance for OST-HER2’s approval process, with regulatory agencies, including the UKMHRA and FDA, signifying their support for the use of historical control data and potential for a conditional approval pathway. Furthermore, the favorable safety and tolerability profile of OST-HER2, along with encouraging indications from multiple regulatory bodies, underscores the therapeutic potential of this treatment in addressing critical needs in oncology for children and young adults.
Bears say
OS Therapies Inc. faces significant financial challenges, including limited revenue generation and the need for substantial capital to fund its ongoing clinical trials, which raises concerns about its ability to sustain operations in the long term. The company’s reliance on external funding and the high costs associated with drug development contribute to its precarious financial position. Additionally, the competitive landscape within the biopharmaceutical industry, particularly for treatments targeting Osteosarcoma and other solid tumors, heightens the risks associated with OS Therapies's market entry and acceptance, further complicating its growth potential.
This aggregate rating is based on analysts' research of OS Therapies Inc and is not a guaranteed prediction by Public.com or investment advice.
OSTX Analyst Forecast & Price Prediction
Start investing in OSTX
Order type
Buy in
Order amount
Est. shares
0 shares